Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Diffuse interstitial lung disease without pleural involvement and high-dose bromocriptine]

E Marsaudon1, D Castet, M F Barrault

  • 1Service de Médecine Interne, Centre Hospitalier de Châteauroux.

Revue Des Maladies Respiratoires
|February 28, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Intermittent thoracic pain].

La Revue de medecine interne·2018
Same author

[A Listeria breast abscess in a man].

La Revue de medecine interne·2018
Same author

[Mondor's disease of penis: A case report].

La Revue de medecine interne·2016
Same author

[Eyelid ptosis revealing a cerebral schistosomiasis].

La Revue de medecine interne·2005
Same author

[Discovery of testicular microlithiasis in the course of Ureaplasma urealyticum urethritis].

La Revue de medecine interne·2000
Same author

[Spinal cord compression due to tophaceous vertebral gout: a case report and literature review].

La Revue de medecine interne·1999
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Bromocriptine, used for Parkinson's disease, can cause lung complications like fibrosis. Regular monitoring is recommended for patients on this medication to detect potential pleuro-pulmonary issues early.

Area of Science:

  • Pulmonology
  • Neurology
  • Pharmacology

Background:

  • Bromocriptine is a dopamine agonist used for Parkinson's disease, hyperprolactinemia, and acromegaly.
  • Pleuro-pulmonary complications, including pleural effusions and lung fibrosis, have been associated with bromocriptine use, particularly at higher doses.

Observation:

  • A case study details a patient with Parkinson's disease experiencing bilateral pulmonary infiltrates and dyspnea after one year of high-dose bromocriptine treatment (105 mg daily).
  • Symptoms emerged after 9 months to 4 years in previously reported cases, with a prevalence of 2-5% after 5 years of treatment.

Findings:

  • The patient's condition improved significantly with both clinical symptoms and chest X-ray findings after discontinuing bromocriptine.
  • Reported complications range from pleural effusions and thickening to parenchymal lung fibrosis, with dosages varying from 20 to 90 mg daily.

Related Experiment Videos

Implications:

  • The pathogenesis of bromocriptine-induced lung disease remains unclear, with theories including vascular, immunological, or toxic fibrogenesis mechanisms.
  • Clinical and radiological monitoring is crucial for patients undergoing bromocriptine therapy to ensure early detection and management of potential pleuro-pulmonary complications.